Cover Image
市場調查報告書

T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e) :開發中產品分析

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 364833
出版日期 內容資訊 英文 47 Pages
訂單完成後即時交付
價格
Back to Top
T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e) :開發中產品分析 T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H2 2017
出版日期: 2017年08月22日 內容資訊: 英文 47 Pages
簡介

本報告提供以T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e) 為標的之治療藥開發相關資訊,提供您開發階段,藥物標的,作用機制,給藥途徑及各分子類型分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e)概要

治療藥的開發

T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e):開發中的產品 - 各開發階段

T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e):開發中的產品 - 各治療範圍

T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e):開發中的產品 - 各適應症

T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e):企業開發中的產品

T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e):大學/機關開發中的產品

T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e):治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e)治療藥的開發企業

  • Amgen Inc.
  • GlaxoSmithKline Plc
  • MacroGenics, Inc.
  • Tiziana Life Sciences Plc
  • Xencor, Inc.

藥物簡介

T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e):暫停中的計劃

T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e):主要消息與新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0971TDB

Summary:

According to the recently published report 'T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H2 2017'; T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - T-Cell surface glycoprotein CD3 epsilon chain also known as CD3E is a polypeptide encoded by the CD3E gene. T-cell surface glycoprotein CD3 epsilon chain interacts with TOP2B, CD3EAPand NCK2. The CD3 complex mediates signal transduction, resulting in T-cell activation and proliferation.

The report 'T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H2 2017' outlays comprehensive information on the T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 3 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Metabolic Disorders, Central Nervous System, Gastrointestinal and Infectious Disease which include indications Type 1 Diabetes (Juvenile Diabetes), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Autoimmune Disorders, Chronic Inflammation, Crohn's Disease (Regional Enteritis), Hepatitis B, Inflammatory Bowel Disease, Kidney Transplant Rejection, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Non-Alcoholic Steatohepatitis (NASH), Primary Biliary Cirrhosis, Psoriasis and Rheumatoid Arthritis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)
  • The report reviews T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics and enlists all their major and minor projects
  • The report assesses T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Overview
    • T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Companies Involved in Therapeutics Development
    • Amgen Inc
    • GlaxoSmithKline Plc
    • MacroGenics Inc
    • Numab Innovation AG
    • SYNIMMUNE GmbH
    • Tiziana Life Sciences Plc
  • T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Drug Profiles
    • Bispecific Monoclonal Antibodies to Target CD3, CD16 and HBsAg for HBV Infection and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • foralumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ND-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • otelixizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TACSYN - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • teplizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XmAb-13551 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Dormant Products
  • T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 28, 2017: Publication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases
      • Mar 14, 2017: Tiziana Life Sciences Appoints Dr. Arun Sanyal to its Scientific Advisory Board
      • Nov 18, 2016: New Publication: Partial Exhaustion of CD8 T Cells in Responders to Anti-CD3 Treatment in New-Onset Type 1 Diabetes
      • Nov 16, 2016: Tiziana Life Sciences Announces New Data with Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases
      • May 19, 2016: Immunotherapy Journal Review of Anti - CD3 Monoclonal Antibodies Highlights Therapeutic Potential of Tizianas Foralumab
      • Jan 11, 2016: Tiziana announces plans for clinical development of foralumab, the company fully human CD3 antibody
      • Jun 28, 2011: MacroGenics Announces Publication Of Protege Phase III Clinical Data Of Teplizumab In The Lancet
      • Jun 23, 2011: MacroGenics To Present Protege Phase III Clinical Data Of Teplizumab In Type 1 Diabetes At ADA In San Diego, US
      • Mar 11, 2011: Tolerx And GSK Announce Phase III Defend-1 Study Of Otelixizumab In Type 1 Diabetes Fails Primary Endpoint
      • Oct 20, 2010: MacroGenics And Lilly Report Pivotal Clinical Trial Of Teplizumab Did Not Meet Primary Efficacy Endpoint
      • Sep 23, 2010: Tolerx Enrolls First Patient In Europe In DEFEND-2 Phase III Clinical Study For Treatment Of Type 1 Diabetes
      • Sep 23, 2010: Tolerx Presents Baseline Data From DEFEND-1 Study At European Association For Study Of Diabetes Annual Meeting
      • Jun 28, 2010: Tolerx Initiates Confirmatory Phase III Trial With Otelixizumab For Type 1 Diabetes
      • Jun 28, 2010: Tolerx Presents Baseline Data From DEFEND-1 Study Validating C-Peptide As Critical Clinical Measure For New-Onset Type 1 Diabetes
      • Mar 17, 2010: Single Short Course of Tolerx's Otelixizumab Provides Prolonged Preservation Of Beta Cell Function
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Amgen Inc, H2 2017
  • Pipeline by GlaxoSmithKline Plc, H2 2017
  • Pipeline by MacroGenics Inc, H2 2017
  • Pipeline by Numab Innovation AG, H2 2017
  • Pipeline by SYNIMMUNE GmbH, H2 2017
  • Pipeline by Tiziana Life Sciences Plc, H2 2017
  • Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top